Abiopharma

🔍 MICEK JOHN (Executive)

Company: Jaguar Health, Inc. (JAGX)

Report Date: 2025-12-11

Detailed Transactions and Holdings:

• Acquired 7,377 shares of Common Stock (Direct)
  Date: 2025-12-11 | Code: A | equity_swap_involved: false | shares_owned_after: 7,430.00 | transaction_form_type: 4 | Footnotes: F1, F2, F4
• Acquired 7,377 shares of Stock Option (right to buy) at $1.44 per share (Derivative)
  Date: 2025-12-11 | Code: A | Expires: 2035-12-11 | equity_swap_involved: false | shares_owned_after: 7,377.00 | transaction_form_type: 4 | Footnotes: F1, F2, F6

Footnotes:

• F1: Granted pursuant to the issuer's 2014 Stock Incentive Plan.
• F2: The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
• F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
• F4: On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.
• F5: On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
• F6: The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer and Napo Therapeutics, S.p.A., the issuer's subsidiary, as applicable.